Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.

about

Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.

P2860

Q51627752-6C37CADA-0E87-4B43-8188-DBEAFD974576

P2860

Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.

Item

http://www.wikidata.org/entity/Q36356633

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Favorable therapeutic response ...... ompared with oral alendronate.

@ast

Favorable therapeutic response ...... ompared with oral alendronate.

@en

type

Item

label

Favorable therapeutic response ...... ompared with oral alendronate.

@ast

Favorable therapeutic response ...... ompared with oral alendronate.

@en

prefLabel

Favorable therapeutic response ...... ompared with oral alendronate.

@ast

Favorable therapeutic response ...... ompared with oral alendronate.

@en

P1476

Favorable therapeutic response ...... compared with oral alendronate

@en

P2093

Ali S Jawad

http://www.w3.org/2001/XMLSchema#string

Jonas Bystrom

http://www.w3.org/2001/XMLSchema#string

Mohammed A Alkhorayef

http://www.w3.org/2001/XMLSchema#string

Mohammed M Al-Bogami

http://www.w3.org/2001/XMLSchema#string

Olufunso A Akanle

http://www.w3.org/2001/XMLSchema#string

Rizgar A Mageed

http://www.w3.org/2001/XMLSchema#string

P2860

The assessment of fracture risk.

Bisphosphonates: the first 40 years.

Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.

Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study.

A reappraisal of generic bisphosphonates in osteoporosis.

Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.

Long-term use of bisphosphonates in osteoporosis.

Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.

The pathogenesis, diagnosis, investigation and management of osteoporosis.

P304

1305-1311

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.15537/SMJ.2015.11.12731

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nasra K Al-Adhoubi

P577

2015-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284554133

http://www.w3.org/2001/XMLSchema#string

P698

26593163

http://www.w3.org/2001/XMLSchema#string

P921

osteoporosis

P932

4673367

http://www.w3.org/2001/XMLSchema#string

Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.

about

P2860

P2860

Favorable therapeutic response of osteoporosis patients to treatment with intravenous zoledronate compared with oral alendronate.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P932